Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy
暂无分享,去创建一个
M. Boccadoro | A. Larocca | C. Conticello | A. Palumbo | A. Liberati | M. Offidani | S. Spada | S. Oliva | S. Grammatico | B. Gamberi | M. Gambella | B. Mantoan | Chiara Pautasso | P. Omede' | E. Marzanati